Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Jun, 2015 | Pages:
58 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Ipsen S.A. - Product Pipeline Review - 2015 Summary Global Markets Direct's, 'Ipsen S.A. - Product Pipeline Review - 2015', provides an overview of the Ipsen S.A.'s pharmaceutical research and development focus. This report provides comprehensive information on the current therapeutic developmental pipeline of Ipsen S.A.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides brief overview of Ipsen S.A. including business description, key information and facts, and its locations and subsidiaries - The report reviews current pipeline of Ipsen S.A.'s human therapeutic division and enlists all their major and minor projects - The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones - Special feature on out-licensed and partnered product portfolio - The report summarizes all the dormant and discontinued pipeline projects - Latest company statement - Latest news and deals relating to the Ipsen S.A.'s pipeline products Reasons to buy - Evaluate Ipsen S.A.'s strategic position with total access to detailed information on its product pipeline - Assess the growth potential of Ipsen S.A. in its therapy areas of focus - Identify new drug targets and therapeutic classes in the Ipsen S.A.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps - Develop strategic initiatives by understanding the focus areas of Ipsen S.A. and exploit collaboration and partnership opportunities - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Plan mergers and acquisitions effectively by identifying the most promising pipeline of Ipsen S.A. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope - Explore the dormant and discontinued projects of Ipsen S.A. and identify potential opportunities in those areas - Avoid Intellectual Property Rights related issues
Table of Contents
Table of Contents 2 List of Tables 5 List of Figures 5 Ipsen S.A. Snapshot 6 Ipsen S.A. Overview 6 Key Information 6 Key Facts 6 Ipsen S.A. - Research and Development Overview 7 Key Therapeutic Areas 7 Ipsen S.A. - Pipeline Review 10 Pipeline Products by Stage of Development 10 Pipeline Products - Monotherapy 11 Pipeline Products - Partnered Products 12 Partnered Products/Combination Treatment Modalities 13 Pipeline Products - Out-Licensed Products 14 Out-Licensed Products/Combination Treatment Modalities 15 Ipsen S.A. - Pipeline Products Glance 16 Ipsen S.A. - Late Stage Pipeline Products 16 Pre-Registration Products/Combination Treatment Modalities 16 Phase III Products/Combination Treatment Modalities 17 Ipsen S.A. - Clinical Stage Pipeline Products 18 Phase II Products/Combination Treatment Modalities 18 Phase I Products/Combination Treatment Modalities 19 Ipsen S.A. - Early Stage Pipeline Products 20 Preclinical Products/Combination Treatment Modalities 20 Discovery Products/Combination Treatment Modalities 21 Ipsen S.A. - Drug Profiles 22 abobotulinumtoxin A 22 Product Description 22 Mechanism of Action 22 R&D Progress 22 lanreotide acetate 24 Product Description 24 Mechanism of Action 24 R&D Progress 24 abobotulinumtoxin A next generation 26 Product Description 26 Mechanism of Action 26 R&D Progress 26 triptorelin pamoate PR 27 Product Description 27 Mechanism of Action 27 R&D Progress 27 BN-82451 29 Product Description 29 Mechanism of Action 29 R&D Progress 29 BIM-23A758 30 Product Description 30 Mechanism of Action 30 R&D Progress 30 Peptides for Endocrine Gland Disorders 31 Product Description 31 Mechanism of Action 31 R&D Progress 31 Peptides for Oncology and Genito Urinary System And Sex Hormones 32 Product Description 32 Mechanism of Action 32 R&D Progress 32 Peptides to Antagonize ACTH Receptor for Cushing's Syndrome 33 Product Description 33 Mechanism of Action 33 R&D Progress 33 Recombinant Protein 1 to Inhibit SNARE for Neurology 34 Product Description 34 Mechanism of Action 34 R&D Progress 34 Recombinant Protein 2 to Inhibit SNARE for Neurology 35 Product Description 35 Mechanism of Action 35 R&D Progress 35 STX-140 36 Product Description 36 Mechanism of Action 36 R&D Progress 36 STX-681 37 Product Description 37 Mechanism of Action 37 R&D Progress 37 SXN-101742 38 Product Description 38 Mechanism of Action 38 R&D Progress 38 SXN-101959 39 Product Description 39 Mechanism of Action 39 R&D Progress 39 Drugs to Antagonize Androgen Receptor for Prostate Cancer 40 Product Description 40 Mechanism of Action 40 R&D Progress 40 Peptides for Endocrine Disease 41 Product Description 41 Mechanism of Action 41 R&D Progress 41 Ipsen S.A. - Pipeline Analysis 42 Ipsen S.A. - Pipeline Products by Target 42 Ipsen S.A. - Pipeline Products by Route of Administration 43 Ipsen S.A. - Pipeline Products by Molecule Type 44 Ipsen S.A. - Pipeline Products by Mechanism of Action 45 Ipsen S.A. - Recent Pipeline Updates 46 Ipsen S.A. - Dormant Projects 51 Ipsen S.A. - Discontinued Pipeline Products 52 Discontinued Pipeline Product Profiles 52 BIM-23A760 52 (mecasermin + somatropin) 52 irosustat 52 taspoglutide 52 Ipsen S.A. - Company Statement 53 Ipsen S.A. - Locations And Subsidiaries 54 Head Office 54 Other Locations & Subsidiaries 54 Appendix 57 Methodology 57 Coverage 57 Secondary Research 57 Primary Research 57 Expert Panel Validation 57 Contact Us 57 Disclaimer 58
List of Tables
Ipsen S.A., Key Information 6 Ipsen S.A., Key Facts 6 Ipsen S.A. - Pipeline by Indication, 2015 8 Ipsen S.A. - Pipeline by Stage of Development, 2015 10 Ipsen S.A. - Monotherapy Products in Pipeline, 2015 11 Ipsen S.A. - Partnered Products in Pipeline, 2015 12 Ipsen S.A. - Partnered Products/ Combination Treatment Modalities, 2015 13 Ipsen S.A. - Out-Licensed Products in Pipeline, 2015 14 Ipsen S.A. - Out-Licensed Products/ Combination Treatment Modalities, 2015 15 Ipsen S.A. - Pre-Registration, 2015 16 Ipsen S.A. - Phase III, 2015 17 Ipsen S.A. - Phase II, 2015 18 Ipsen S.A. - Phase I, 2015 19 Ipsen S.A. - Preclinical, 2015 20 Ipsen S.A. - Discovery, 2015 21 Ipsen S.A. - Pipeline by Target, 2015 42 Ipsen S.A. - Pipeline by Route of Administration, 2015 43 Ipsen S.A. - Pipeline by Molecule Type, 2015 44 Ipsen S.A. - Pipeline Products by Mechanism of Action, 2015 45 Ipsen S.A. - Recent Pipeline Updates, 2015 46 Ipsen S.A. - Dormant Developmental Projects,2015 51 Ipsen S.A. - Discontinued Pipeline Products, 2015 52 Ipsen S.A., Subsidiaries 54
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
